# name
Pancreatic cancer mortality and associated productivity losses in Spain: A population-based estimate (2013-2022)

# metadata.dc.description.abstract[].value
Background: Pancreatic cancer remains as the cancer type with the poorest prognosis, characterized by rising
incidence and mortality rates. This disease imposes a substantial economic burden, including productivity losses
resulting from premature mortality.
Objective: This study aims to estimate productivity losses due to premature deaths from pancreatic cancer in
Spain during the period 2013–2022.
Methods: Productivity costs were quantified using a simulation model based on the human capital method. Data
on mortality rates, average salaries, and employment rates were obtained from the Spanish Instituto Nacional de
Estadística for the entire study period.
Results: Between 2013 and 2022, the number of deaths due to pancreatic cancer in Spain increased from 6039 to
7973 and, by 2022, pancreatic cancer became the leading cause of death among digestive system tumours. This
rise was accompanied by an increase in Years of Potential Labour Productive Life Lost due to premature death
(YPLPLL): for men, YPLPLL grew from 8146 in 2013 to 9650 in 2022, and for women, from 4699 to 6053 over
the same period. Consequently, labour productivity losses were estimated at €253.40 million in 2013, rising to
€406.20 million in 2022, with a cumulative cost of €3253.97 million during the study period.
Conclusions: These findings provide valuable insights into the societal costs of pancreatic cancer in Spain. Investments in targeted strategies focusing on prevention, early detection, and advanced-stage therapies for
pancreatic cancer have the potential to significantly reduce its future economic and health impacts.

# metadata.dc.rights[].value
cc-by-nc-nd (c) Darbà, Josep et al., 2026

# metadata.dc.source[].value
Articles publicats en revistes (Economia)

# metadata.dc.title[].value
Pancreatic cancer mortality and associated productivity losses in Spain: A population-based estimate (2013-2022)